MSB 10.4% $1.49 mesoblast limited

@kervio thank you for taking the time to explain this in...

  1. Yor
    150 Posts.
    lightbulb Created with Sketch. 70
    @kervio thank you for taking the time to explain this in details. A couple of remarks: the trial is powered now with 21 hospitals, up from 15 in August, and has enrolled 50% in mid October. We may hope that 60% enrollment would be achieved in November when the DSMB will come up with the 45% interim analysis. Also, as you pointed out, SOC ensures better results as 65% of ventilated patients decease down from 85% in April, about 20% improvement. I feel this may help not only placebo but maybe also the patients who receive the treatment. If we improve by the same proportion, 20%, we would be closer to 80% than 75% (9/12) survival rate. This in turn affects the differential.
    Let’s hope, and be patient
    GL all
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.